Successful Treatment with Modified FOLFOX6 and Panitumumab in a Cecal Cancer Patient Undergoing Hemodialysis

Mariko Kobayashi; Shinji Endo; Yukako Hamano; Mamiko Imanishi; Daisuke Akutsu; Akinori Sugaya; Daisuke Ochi; Toshikazu Moriwaki; Ichinosuke Hyodo

doi:10.2169/internalmedicine.55.5113

CASE REPORTS

Successful Treatment with Modified FOLFOX6 and Panitumumab in a Cecal Cancer Patient Undergoing Hemodialysis

Mariko Kobayashi, Shinji Endo, Yukako Hamano, Mamiko Imanishi, Daisuke Akutsu, Akinori Sugaya, Daisuke Ochi, Toshikazu Moriwaki, Ichinosuke Hyodo

著者情報

Mariko Kobayashi
Division of Gastroenterology, University of Tsukuba Hospital, Japan
Division of Gastroenterology, Tsukuba Memorial Hospital, Japan
Shinji Endo
Division of Gastroenterology, University of Tsukuba Hospital, Japan
Yukako Hamano
Division of Gastroenterology, University of Tsukuba Hospital, Japan
Mamiko Imanishi
Division of Gastroenterology, University of Tsukuba Hospital, Japan
Daisuke Akutsu
Division of Gastroenterology, University of Tsukuba Hospital, Japan
Akinori Sugaya
Division of Gastroenterology, University of Tsukuba Hospital, Japan
Daisuke Ochi
Division of Gastroenterology, University of Tsukuba Hospital, Japan
Toshikazu Moriwaki
Division of Gastroenterology, University of Tsukuba Hospital, Japan
Ichinosuke Hyodo
Division of Gastroenterology, University of Tsukuba Hospital, Japan

キーワード: colorectal cancer, hemodialysis, panitumumab, mFOLFOX6

ジャーナルオープンアクセス

2016 年 55 巻 2 号 p. 127-130

DOI https://doi.org/10.2169/internalmedicine.55.5113

詳細

抄録

Combination chemotherapy of mFOLFOX6 (5-fluorouracil, leucovorin, and oxaliplatin) plus panitumumab, a fully human monoclonal antibody against epidermal growth factor receptor (EGFR), is one of the standard treatments for metastatic colorectal cancer (mCRC) without KRAS mutation. A few reports suggested no need of dose adjustment of cetuximab, a similar chimeric anti-EGFR antibody, in patients with renal impairment. However, panitumumab combined with cytotoxic drugs for hemodialysis patients has not been reported. We herein report a case of a hemodialysis mCRC patient successfully treated with mFOLFOX6 and panitumumab combination therapy.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）